JDRF Blog

Latest in Research News

  • JDRF Research Strategy: Cures and Improving Lives

    May 31, 2019

    They shared new developments and applauded the speed of scientific advancements. At this year’s Strategic Research Session, the tone was dynamic as...

  • FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia

    September 11, 2019

    “The approval of the GVOKE HypoPenTM is an important step forward for people with diabetes. Severe hypoglycemia is a terrifying and dangerous...

  • FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years

    August 5, 2019

    The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention or delay...

  • A Win for the European T1D Community: Zynquista (sotagliflozin) Approved for Type 1 Diabetes

    April 29, 2019

    In a second win for the type 1 diabetes (T1D) community, the European Commission has approved Zynquista™ (sotagliflozin) for use in adults...

  • What is nPOD?

    April 17, 2019

    The human pancreas is very difficult to study, as JDRF-funded scientists well know. It cannot be imaged or safely biopsied from a...

  • European Commission Has Approved Forxiga for Adults with Type 1 Diabetes

    March 25, 2019

    It’s official: The European Commission has approved Forxiga® (dapagliflozin and marketed in the United States as Farxiga®) for adults with type 1...

  • Can a Snail Hold the Key to Better Blood Sugar Control?

    February 26, 2019

    “Rapid-acting” insulin analogs were introduced commercially in the 1990s; however, these insulins are still slower than insulin secreted from a nondiabetic pancreas,...